Mr Karun Rishi
USAIC's BioPharma & Healthcare Summit 2015 will bring together key stakeholders from the industry, academia, investors, foundations and government to engage in active debate and idea generation on routes for successful collaboration between global BioPharma companies and academia, and India's BioPharma industry and academia.
The Summit will focus on the Big Data, therapeutic areas of oncology, cardiovascular and metabolic diseases; neurodegenerative diseases; along with discussions on BioPharma R&D strategy & trends; Industry-Academic Partnerships; Funding Innovation and M&A trends. PricewaterhouseCoopers LLP (PwC) is the Knowledge Partner. USAIC commissioned PwC USA Position Paper will be released at the Summit.
The annual summit is a must attend gathering for global BioPharma industry leaders, academicians and investors. Over eight prominent global R&D heads are participating besides the therapeutic R&D heads of CVMD, oncology and neurosciences. There will be fireside chat between Dr Tachi Yamada-Takeda and Mr Christopher Viehbacher, former CEO of Sanofi. For the first time, Global Chief Medical Officer Panel is being introduced. It is led by Dr Michael Rosenblatt, EVP and chief medical officer of Merck and Co.
"Global BioPharma innovation is all about collaborative research. Startups, big BioPharma and academics need to work together for a common goal of bringing novel therapeutics which save human lives or improve the quality of lives worldwide," said Mr Karun Rishi, President of the USA India Chamber of Commerce. It is time India with one-sixth of the world population plays a leading role in the global BioPharma innovation ecosystem. This very well fits into Prime Minister Narendra Modi's "Make in India" initiative. Besides an economic value creation, BioPharma and ealthcare innovation has an added advantage of India playing a key role in alleviating global human sufferings by way of new drugs and therapies," said Mr Rishi.
"Fundamental, broad-scale innovation is critical if we want to remain successful as an industry," said Mr Andy Plump, chief medical and scientific officer, Takeda and USAIC Advisory Board Member. "The breadth of innovative science and discovery occurring in India is truly impressive and Takeda is enthusiastic about forging meaningful, long-term partnerships there. USAIC is an important venue to help spark those conversations that we hope will lead to important advances for patients."
"The only way we can make the 'right to healthcare' truly universal is through collaborative innovation where companies come together to share knowledge, risks and opportunities. Synergistic partnerships between Indian and US entities have helped take affordable novel drugs and low-cost bio-medical equipment to patients globally. USAIC's annual BioPharma & Healthcare Summit in Boston provides a vital platform to connect key stakeholders who want to make a difference to global healthcare. I look forward to participating in the summit and hope to see you there," said Dr Kiran Mazumdar Shaw, CMD, Biocon and USAIC Advisory Board member.
Collaborative research is critical to drive medical innovation, especially as it is becoming increasingly important for both companies and hospitals to prioritize their research programs," said Mr Martin Mackay, executive vice president and global head of R&D at Alexion and USAIC Advisory Board member. "At Alexion, we focus exclusively on developing therapies that have the potential to transform the lives of patients suffering from severe and rare diseases, and we are open to collaboration opportunities that help us work towards our goal of providing hope to patients who are often underserved due to the rarity of their disorder."
